The hollow fibre model - Facilitating anti-cancer pre-clinical pharmacodynamics and improving animal welfare

International Journal of Oncology

Volumn 29, Issue 6, 2006, Pages 1493-1499

  Suggitt, Marie ^a   Cooper, Patricia A ^a   Shnyder, Steven D ^a   Bibby, Michael C ^a  

^a UNIVERSITY OF BRADFORD   (United Kingdom)

Author keywords

3Rs; Hollow fibre assay; Pharmacodynamics

Indexed keywords

1,1' ((PROPANE 1,3 DIYL)DIOXY)BIS(7 METHOXY 2 METHYLIDENE 1,2,3,10,11,11A HEXAHYDRO 5H PYRROLO(2,1 C)(1,4)BENZODIAZEPIN 5,11 DIONE); 1,1'-((PROPANE-1,3-DIYL)DIOXY)BIS(7-METHOXY-2-METHYLIDENE-1,2,3,10,11,11A-HEXAHYDRO-5H-PYRROLO(2,1-C)(1,4)BENZODIAZEPIN-5,11-DIONE); AMINOACRIDINE DERIVATIVE; BENZODIAZEPINE DERIVATIVE; IMIDACRINE; MITOMYCIN; PYRROLE DERIVATIVE;

ANIMAL; ANIMAL WELFARE; ARTICLE; CANCER TRANSPLANTATION; CELL GROWTH; CELL STRAIN HL 60; CELL STRAIN HT29; COMET ASSAY; DRUG SCREENING; ETHICS; FEMALE; FLUORESCENCE MICROSCOPY; HUMAN; METHODOLOGY; MOUSE; PHYSIOLOGY; XENOGRAFT;

AMINOACRIDINES; ANIMAL WELFARE; ANIMALS; BENZODIAZEPINONES; CELL GROWTH PROCESSES; COMET ASSAY; DRUG SCREENING ASSAYS, ANTITUMOR; FEMALE; HL-60 CELLS; HT29 CELLS; HUMANS; MICE; MICROSCOPY, FLUORESCENCE; MITOMYCIN; NEOPLASM TRANSPLANTATION; PYRROLES; TRANSPLANTATION, HETEROLOGOUS;

EID: 36549004815     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo.29.6.1493     Document Type: Article

References (40)

1. Russell WMS and Burch RL: The Principles of Human Experimental Technique. Methuen & Co. Ltd., London, 1959.
2. Schechtman LM: Implementation of the 3Rs (refinement, reduction, and replacement): validation and regulatory acceptance considerations for alternative toxicological test methods. Ilar J 43 (Suppl.): S85-S94, 2002.
3. Hollingshead MG, Alley MC, Camalier RF, et al: In vivo cultivation of tumor cells in hollow fibers. Life Sci 57: 131-141, 1995.
4. Taggart BR, Harrington P and Hollingshead M: HIV hollow fiber SCID model for antiviral therapy comparison with SCID/hu model. Antiviral Res 63: 1-6, 2004.
5. Mosmann T: Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods 65: 55-63, 1983.
6. Suggitt M and Bibby M: 50 years of preclinical anti-cancer drug screening - empirical to target-driven approaches. Clin Cancer Res (Review) 11: 971-981, 2005.
7. Suggitt M, Swaine DJ, Pettit GR and Bibby MC: Characterisation of the hollow fibre assay for the determination of microtubule disruption in vivo. Clin Cancer Res 10: 6677-6685, 2004.
8. Leong CO, Suggitt M, Swaine DJ, Bibby MC, Stevens MF and Bradshaw TD: In vitro, in vivo, and in silico analyses of the antitumor activity of 2-(4-amino-3-methylphenyl)-5-fluorobenzothiazoles. Mol Cancer Ther 3: 1565-1575, 2004.
9. Hall LA, Krauthauser CM, Wexler RS, Hollingshead MG, Slee AM and Kerr JS: The hollow fiber assay: continued characterization with novel approaches. Anticancer Res 20: 903-911, 2000.
10. Krauthauser CM, Hall LA, Wexler RS et al: Regulation of gene expression and cell growth in vivo by tetracycline using the hollow fiber assay. Anticancer Res 21: 869-872, 2001.
11. Sadar MD, Akopian VA and Beraldi E: Characterization of a new in vivo hollow fiber model for the study of progression of prostate cancer to androgen independence. Mol Cancer Ther 1: 629-637, 2002.
12. Shnyder SD, Hasan J, Cooper PA, et al: Development of a modified hollow fibre assay for studying agents targeting the tumour neovasculature. Anticancer Res 25: 1889-1894, 2005.
13. Thurston DE: Advances in the study of pyrrolo[2,1-c][1,4]-benzodiazapine (PBD) antitumour antibiotics. In: Molecular Aspects of Anticancer Drug-DNA Interactions. Macmilan. London, p53, 1993.
14. Cholody WM, Martelli S, Paradziej-Lukowicz J and Konopa J: 5-[(Aminoalkyl)amino]imidazo[4,5,1-de]acridin-6-ones as a novel class of antineoplastic agents. Synthesis and biological activity. J Med Chem 33: 49-52, 1990.
15. Giard DJ, Aaronson SA, Todaro GJ, et al: In vitro cultivation of human tumors: establishment of cell lines derived from a series of solid tumors. J Natl Cancer Inst 51: 1417-1423, 1973.
16. Collins SJ: Continuous growth and differentiation of human myeloid leukaemic cells in suspension culture. Nature 270: 347-349, 1977.
17. Fogh J: One hundred and twenty seven cultured human tumour cell lines producing tumours in mice. J Natl Cancer Inst 59: 221-226, 1977.
18. Workman P, Balmain A, Hickman JA, et al: United Kingdom Co-ordinating Committee on Cancer Research (UKCCCR) Guidelines for the Welfare of Animals in Experimental Neoplasia (2nd edition). Br J Cancer 77: 1-10, 1988.
19. Cowen SE: Vascular characterisation and evaluation of vasomanipulation to potentiate therapy in in vivo tumour models. University of Bradford, PhD Thesis, 1995.
20. Burger AM, Double JA, Konopa J and Bibby MC: Preclinical evaluation of novel imidazoacridinone derivatives with potent activity against experimental colorectal cancer. Br J Cancer 74: 1369-1374, 1996.
21. Calabrese CR, Bibby MC, Double JA and Loadman PM: Pharmacokinetics and tissue distribution of the imidazoacridinone C1311 in tumour bearing mice. Cancer Chemother Pharmacol 42: 379-385, 1998.
22. Hartley JA, Spanswick VJ, Brooks N, et al: SJG-136 (NSC 694501), a novel rationally designed DNA minor groove interstrand cross-linking agent with potent and broad spectrum antitumor activity: part 1: cellular pharmacology, in vitro and initial in vivo antitumor activity. Cancer Res 64: 6693-6699, 2004.
23. Singh NP, McCoy MT, Tice RR and Schneider EL: A simple technique for quantitation of low levels of DNA damage in individual cells. Exp Cell Res 175: 184-191, 1988.
24. Szmigiero L and Studzian K: H2O2 as a DNA fragmenting agent in the alkaline elution interstrand crosslinking and DNA-protein crosslinking assays. Anal Biochem 168: 88-93, 1988.
25. 32]P-labelling. Clin Cancer Res 7: 1033-1042, 2001.
26. Alley MC, Hollingshead MG, Pacula-Cox CM, et al: SJG-136 (NSC 694501), a novel rationally designed DNA minor groove interstrand cross-linking agent with potent and broad spectrum antitumor activity: part 2: efficacy evaluations. Cancer Res 64: 6700-6706, 2004.
27. Burger AM, Jenkins TC, Double JA and Bibby MC: Cellular uptake, cytotoxicity and DNA-binding studies of the novel imidazoacridinone antineoplastic agent C1311. Br J Cancer 81: 367-375, 1999.
28. Holwell SE, Cooper PA, Grosios K, et al: Combretastatin A-1 phosphate a novel tubulin-binding agent with in vivo anti vascular effects in experimental tumours. Anticancer Res 22: 707-711, 2002.
29. Scholz CC, Berger DP, Winterhalter BR, Henss H and Fiebig HH: Correlation of drug response in patients and in the clonogenic assay with solid human tumour xenografts. Eur J Cancer 26: 901-905, 1990.
30. Van Dyke T and Jacks T: Cancer modeling in the modern era: progress and challenges. Cell 108: 135-144, 2002.
31. Decker S, Hollingshead M, Bonomi CA, Carter JP and Sausville EA: The hollow fibre model in cancer drug screening; the NCI experience. Eur J Cancer 40: 821-826, 2004. (Pubitemid 38519760)
32. Johnson JI, Decker S, Zaharevitz D, et al: Relationships between drug activity in NCI preclinical in vitro and in vivo models and early clinical trials. Br J Cancer 84: 1424-1431, 2001. (Pubitemid 32522115)
33. Parulekar WR and Eisenhauer EA: Phase I trial design for solid tumor studies of targeted, non-cytotoxic agents: theory and practice. J Natl Cancer Inst 96: 990-997, 2004.
34. Flecknell P: Replacement refinement and reduction. ALTEX 19: 7378, 2002.
35. Festing MF: Principles: the need for better experimental design. Trends Pharmacol Sci 24: 341-345, 2003.
36. Chu MY, Lipsky MH, Yee LK, et al: Predictive sensitivity of human cancer cells in vivo using semipermeable polysulfone fibers. Pharmacology 56: 318-326, 1998.
37. Jonsson E, Friberg LE, Karlsson MO, et al: Determination of drug effect on tumour cells, host animal toxicity and drug pharmacokinetics in a hollow-fibre model in rats. Cancer Chemother Pharmacol 46: 493-500, 2000.
38. Jonsson E, Friberg LE, Karlsson MO, et al: In vivo activity of CHS 828 on hollow-fibre cultures of primary human tumour cells from patients. Cancer Lett 162: 193-200, 2001.
39. Mi Q, Cui B, Silva GL, et al: Pervilleines B and C, new tropane alkaloid aromatic esters that reverse the multidrug-resistance in the hollow fiber assay. Cancer Lett 184: 13-20, 2002. (Pubitemid 34718102)
40. Mi Q, Cui B, Silva GL, et al: Pervilleine A, a novel tropane alkaloid that reverses the multidrug-resistance phenotype. Cancer Res 61: 4030-4037, 2001. (Pubitemid 32720967)